系统性肥大细胞增多症。

I. Markou, M. Pagoni, T. Tegos, G. Andreou, D. Rontogianni, Nicolaos Harhalakis
{"title":"系统性肥大细胞增多症。","authors":"I. Markou, M. Pagoni, T. Tegos, G. Andreou, D. Rontogianni, Nicolaos Harhalakis","doi":"10.32388/qzbfdh","DOIUrl":null,"url":null,"abstract":"A 64-year-old man was admitted to the Hematology ward in July 2012 due to neutropenia and thrombocytopenia. The only symptom in the month preceding his admission was significant weight loss. Based on clinical and laboratory investigations, specifically bone marrow aspiration and biopsy (Figure), the patient was diagnosed with aggressive systemic mastocytosis (WHO 2008 ICD-0 code 9741/3). The patient initially received treatment with cladribine 8.5 mg once daily in 2-hour intravenous infusion for a 5-day period/28-day cycle. Following the completion of a 5-cycle treatment course with cladribine, thrombocytopenia improved, but there was no significant change in neutropenia, while the hematocrit remained stable. However, the patient did not show any clinical improvement. Thus, he was reevaluated with bone marrow biopsy, which showed 40% infiltration by malignant mast cells. There was underlying disease of myeloblastic/myeloproliferative neoplasm unclassifiable with 3% IMAGES IN MEDICINE","PeriodicalId":8175,"journal":{"name":"Archives of dermatology","volume":"92 4 1","pages":"481-2"},"PeriodicalIF":0.0000,"publicationDate":"2020-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Systemic mastocytosis.\",\"authors\":\"I. Markou, M. Pagoni, T. Tegos, G. Andreou, D. Rontogianni, Nicolaos Harhalakis\",\"doi\":\"10.32388/qzbfdh\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A 64-year-old man was admitted to the Hematology ward in July 2012 due to neutropenia and thrombocytopenia. The only symptom in the month preceding his admission was significant weight loss. Based on clinical and laboratory investigations, specifically bone marrow aspiration and biopsy (Figure), the patient was diagnosed with aggressive systemic mastocytosis (WHO 2008 ICD-0 code 9741/3). The patient initially received treatment with cladribine 8.5 mg once daily in 2-hour intravenous infusion for a 5-day period/28-day cycle. Following the completion of a 5-cycle treatment course with cladribine, thrombocytopenia improved, but there was no significant change in neutropenia, while the hematocrit remained stable. However, the patient did not show any clinical improvement. Thus, he was reevaluated with bone marrow biopsy, which showed 40% infiltration by malignant mast cells. There was underlying disease of myeloblastic/myeloproliferative neoplasm unclassifiable with 3% IMAGES IN MEDICINE\",\"PeriodicalId\":8175,\"journal\":{\"name\":\"Archives of dermatology\",\"volume\":\"92 4 1\",\"pages\":\"481-2\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-02-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of dermatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32388/qzbfdh\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32388/qzbfdh","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

2012年7月,一名64岁男子因中性粒细胞减少症和血小板减少症住进血液科病房。入院前一个月的唯一症状是体重明显减轻。根据临床和实验室调查,特别是骨髓抽吸和活检(图),患者被诊断为侵袭性全身肥大细胞增多症(世界卫生组织2008 ICD-0代码9741/3)。患者最初接受了克拉屈滨8.5 mg的治疗,每天一次,静脉滴注2小时,为期5天/28天。克拉屈滨完成5个周期的疗程后,血小板减少症有所改善,但中性粒细胞减少症没有显著变化,而红细胞压积保持稳定。然而,患者没有表现出任何临床改善。因此,他通过骨髓活检进行了重新评估,骨髓活检显示40%的恶性肥大细胞浸润。存在骨髓母细胞/骨髓增生性肿瘤的潜在疾病,3%的医学图像无法分类
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Systemic mastocytosis.
A 64-year-old man was admitted to the Hematology ward in July 2012 due to neutropenia and thrombocytopenia. The only symptom in the month preceding his admission was significant weight loss. Based on clinical and laboratory investigations, specifically bone marrow aspiration and biopsy (Figure), the patient was diagnosed with aggressive systemic mastocytosis (WHO 2008 ICD-0 code 9741/3). The patient initially received treatment with cladribine 8.5 mg once daily in 2-hour intravenous infusion for a 5-day period/28-day cycle. Following the completion of a 5-cycle treatment course with cladribine, thrombocytopenia improved, but there was no significant change in neutropenia, while the hematocrit remained stable. However, the patient did not show any clinical improvement. Thus, he was reevaluated with bone marrow biopsy, which showed 40% infiltration by malignant mast cells. There was underlying disease of myeloblastic/myeloproliferative neoplasm unclassifiable with 3% IMAGES IN MEDICINE
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Archives of dermatology
Archives of dermatology 医学-皮肤病学
自引率
0.00%
发文量
0
审稿时长
4-8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信